CBAY
Cymabay Therapeutics
CBAY
CBAY
Delisted
CBAY was delisted on the 21st of March, 2024.
139 hedge funds and large institutions have $775M invested in Cymabay Therapeutics in 2023 Q1 according to their latest regulatory filings, with 42 funds opening new positions, 43 increasing their positions, 37 reducing their positions, and 20 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
18% more funds holding
Funds holding: 118 → 139 (+21)
16% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 37
Holders
139
Holding in Top 10
10
Calls
$6.51M
Puts
$3.42M
Top Buyers
| 1 | +$54.5M | |
| 2 | +$34M | |
| 3 | +$27.9M | |
| 4 |
PA
Perceptive Advisors
New York
|
+$27.9M |
| 5 |
OCA
Octagon Capital Advisors
New York
|
+$23.6M |
Top Sellers
| 1 | -$32.4M | |
| 2 | -$24.9M | |
| 3 | -$13.6M | |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$9.09M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$9.02M |